reminyl XL® (No. 139/04)

Shire Pharmaceuticals

Product Update

5 November 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

New formulation of existing therapy.

Galantamine hydrobromide as Reminyl XL® prolonged-release capsules is accepted for use in NHS Scotland for the treatment of mild-to-moderately severe dementia in Alzheimer's disease in patients for whom therapy with galantamine is appropriate. It allows the reduction of dosing frequency to once daily and, at a given dose, involves no additional cost compared with immediate-release formulations of galantamine.

Advice context:

No part of this advice may be used without the whole of the advice quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 29 October, 2004.

Chairman,
Scottish Medicines Consortium

Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP
Telephone 0141 225 6989 Fax 0141 249 9981
E-mail: rmurray@htbs.org.uk